Dana-Farber Cancer Institute | Strategic Alliance Partners

February 14, 2022

It is a life-changing experience to see people take the hurt, suffering, pain, and loss of cancer and transform it into a superhuman force for good and for hope.

February 08, 2022

Health care disparities remain a major issue in cancer care, and factors contributing to this inequality stretch far beyond access to clinical care.

February 07, 2022

A combination of two drugs that open the floodgates to an immune system attack on cancer curtailed tumor growth in some patients with non–small cell lung cancer that was resistant to a single immunotherapy agent.

February 04, 2022

Jacob Sands, MD, physician, discusses the importance of next-generation sequencing testing in lung cancer.

February 03, 2022

NECS to be the first and only affiliate member of the Dana-Farber Cancer Institute.

January 24, 2022

Over a 42-month period, the combination of nivolumab and ipilimumab induced a longer treatment-free survival compared with sunitinib (Sutent) when used as frontline therapy in patients with advanced renal cell carcinoma.

January 19, 2022

Venetoclax proved to be safe and highly active when used in patients with relapsed or refractory Waldenström macroglobulinemia, including those who previously received BTK inhibitors and those harboring CXCR4 mutations.

January 14, 2022

Sara M. Tolaney, MD, MPH, sheds light on zanidatamab and the data reported with the agent in combination with chemotherapy for the treatment of patients with HER2-positive breast cancer. 

January 13, 2022

Christopher S. Lathan, MD, MS, MPH, discusses the lack of dissemination and implementation of evidence-based health care delivery innovations focused on addressing disparities in care.

January 12, 2022

Ian E. Krop, MD, PhD, discusses progress made in 2021 in the management of HER2-positive breast cancer.

January 11, 2022

Following an extensive, nationwide search, Goldie Taylor has been named Senior Vice President, Chief Communication and Marketing Officer at Dana-Farber Cancer Institute.

January 06, 2022

The combination of tucatinib, trastuzumab, and capecitabine continued to produce an improvement in overall survival compared with trastuzumab/capecitabine alone in patients with HER2-positive metastatic breast cancer who had stable or active brain metastases.

January 05, 2022

Sara M. Tolaney, MD, MPH, chief, discusses the importance of evaluating enobosarm in metastatic estrogen receptor–positive, HER2-negative breast cancer.

January 05, 2022

Sara M. Tolaney, MD, MPH, discusses the mechanism of action that makes bispecific antibodies an intriguing approach in managing HER2-positive breast cancer, efficacy data with zanidatamab that were presented during the 2021 SABCS, and her thoughts on sequencing strategies with bispecific antibodies among other agents in the paradigm.

January 04, 2022

Sara Tolaney, MD, MPH, discusses the data with the oral selective estrogen receptor degrader, elacestrant, and the androgen receptor agonist, enobosarm, in estrogen receptor–positive, HER2-negative breast cancer.

December 22, 2021

Cancer physicians have long disagreed about whether stem cell transplants from donors with an asymptomatic blood condition called clonal hematopoiesis put recipients at risk for subsequent health problems.

December 22, 2021

Investigators hope to improve upon the efficacy and tolerability of androgens in the treatment of breast cancer with the October 13, 2021, initiation of the phase 3 ARTEST trial.

December 21, 2021

Approval of the drug abatacept opens up bone marrow transplant as an option for many more patients with cancer or blood disorders — especially patients of diverse ethnicities, who have extra difficulty finding a good match

December 20, 2021

A phase 3 clinical trial will compare the safety and efficacy of a co-formulation of pembrolizumab and quavonlimab plus lenvatinib, and that of pembrolizumab, belzutifan, and lenvatinib, vs pembrolizumab/lenvatinib alone in the frontline treatment of patients with advanced renal cell carcinoma.

December 17, 2021

Pembrolizumab demonstrated a statistically significant and clinically meaningful improvement in disease-free survival vs placebo as a postnephrectomy adjuvant therapy in patients with renal cell carcinoma at intermediate-high or high risk of recurrence, and in those who are M1 with no evidence of disease.